• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Solventum partners with SprintRay to disrupt the digital dentistry market with high-quality, permanent same-day restorations

    3/25/25 6:00:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care
    Get the next $SOLV alert in real time by email

    In this first-of-its-kind partnership for its Dental Solutions business, Solventum, formerly 3M Health Care, is striving to focus on longevity and durability of permanent same-day restorative dental offerings, reaffirming its commitment to solving industry's toughest problems

    Partnership aims to integrate innovative new material science and disruptive technology like chairside 3D printing to optimize workflows, enhance procedural efficiency and benefit both patients and practitioners

    ST. PAUL, Minn., March 25, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV), the leader in dental composites and restorative dentistry, today announced a strategic partnership with SprintRay, a leading provider of chairside 3D dental printing, to meet the needs of dentists with in-office chairside 3D printed crowns, inlays, onlays and more. This research and development (R&D) and commercialization agreement is focused on developing and bringing to market high-quality, durable and permanent same-day restorations – with the quality patients and dentists expect from the current multi-visit laboratory fabricated procedures.

    Solventum: Group portrait of a team of three dental professionals on a dark green background.

    Solventum Dental Solutions connects leading-edge materials with data science to help dentists solve their toughest challenges with products such as Filtek™ Easy Match Universal Restorative, Filtek™ Matrix, Scotchbond™ Universal and RelyX™ Universal Cement. SprintRay offers innovative chairside end-to-end 3D printing ecosystems, which create a platform for a wide range of restorative dental applications.

    With Solventum's legacy of best-in-class material science with leading restorative materials, and SprintRay's innovative technology, the partnership aims to bring to market the first permanent chairside, 3D printed crown. Together, Solventum and SprintRay anticipate improvement in patient experience and outcomes through fewer office visits – driving practice efficiency, and ultimately, delivering the outcomes patients and providers demand.

    "Imagine a world where your dentist can create a crown that can last decades in a matter of minutes," said Karim Mansour, President, Dental Solutions, Solventum. "We believe this partnership will revolutionize the way dentists and orthodontists care for patients with in-office production, offering a simplified procedure that we anticipate will improve outcomes and experiences, reduce chair time and lower treatment costs. This collaboration allows us to integrate the latest technological advancements into our proven restorative solutions, ensuring we remain at the forefront of dental innovation to deliver unparalleled care to our patients."

    Offering cutting-edge 3D printing technology directly to dentists and orthodontists will streamline care for patients and providers, allowing the delivery of same-visit dentistry and introducing a market for permanent 3D printed crowns, inlays, onlays and more. 

    "Together, we can make a significant impact in restorative dentistry by building exceptional products for same-visit treatment," said SprintRay CEO Amir Mansouri. "Our partnership with Solventum is a key collaboration and commitment to making a difference in people's oral health as well as enabling high-quality and cost-effective dental restorations across the globe."

    The announcement of the partnership aligns with Solventum's legacy of quality material science and is one example of biasing resources towards growth while strengthening digital capabilities, two elements of Solventum's previously announced three-phased plan. As the winner of seven Dental Advisor awards in 2024, the partnership follows four new product introductions launched in 2024, including:

    • 3M™ Clarity™ Precision Grip Attachments, the first 3D printed aligner attachments
    • 3M™ Clinpro™ Clear Fluoride Treatment, a new water-based formula for smoother application and a more comfortable patient experience
    • Clarity™ Flex + Force Aligners, new proprietary multi-layer copolymer extruded in different thicknesses to best express varying degrees of movement
    • 3M™ Filtek™ Easy Match Universal Restorative features naturally adaptive opacity and offers an intuitive shade selection process to simplify direct restorative procedures

    Solventum will share more details about the strategic partnership at the International Dental Show (IDS) 2025 on March 26 in Cologne, Germany.

    About Solventum

    At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients' lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.

    Forward-Looking Statements

    This news release contains forward-looking information about Solventum's financial results, estimates, and business prospects that involve substantial risks and uncertainties. In particular, statements regarding the future performance of Solventum, including guidance for 2024, are forward-looking statements. You can identify these statements by the use of words such as "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "guidance," "intends," "may," "outlook," "plans," "projects," "seeks," "sees," "should," "targets," "will," "would," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Among the factors that could cause actual results to differ materially are the following: (1) the effects of, and changes in, worldwide economic, political, regulatory, international, trade and geopolitical conditions, natural disasters, war, public health crises, and other events beyond Solventum's control; (2) operational execution risks; (3) damage to our reputation or our brands; (4) risks from acquisitions, strategic alliances, divestitures and other strategic events; (5) ; the highly competitive environment in which Solventum operates and consolidation in the healthcare industry; (6) reduction in customers' research budgets or government funding; (7) the timing and market acceptance of Solventum's new product and service offerings; (8) ongoing working relationships with certain key healthcare professionals; (9) changes in reimbursement practices of governments or private payers or other cost containment measures; (10) Solventum's ability to obtain components or raw materials supplied by third parties and other manufacturing and related supply chain difficulties, interruptions, and disruptive factors; (11) risks related to the highly regulated environment in which Solventum operates; (12) Solventum's failure to obtain, maintain, protect, or effectively enforce its intellectual property ("IP") rights.

    Changes in such assumptions or factors could produce significantly different results. A further description of these factors is located under "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors" in Solventum's periodic reports on file with the U.S. Securities & Exchange Commission. Solventum assumes no obligation to update any forward-looking statements discussed herein as a result of new information or future events or developments.

    Solventum Logo (PRNewsfoto/3M Healthcare US Opco  LLC)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/solventum-partners-with-sprintray-to-disrupt-the-digital-dentistry-market-with-high-quality-permanent-same-day-restorations-302411305.html

    SOURCE Solventum

    Get the next $SOLV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SOLV

    DatePrice TargetRatingAnalyst
    12/4/2024$70.00Neutral
    Mizuho
    10/8/2024$82.00Buy
    Stifel
    10/7/2024$71.00Neutral
    Piper Sandler
    9/26/2024Peer Perform
    Wolfe Research
    9/5/2024Neutral
    BTIG Research
    6/24/2024Hold
    Argus
    5/30/2024$54.00Sell
    Goldman
    More analyst ratings

    $SOLV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Alban Carlos

      4 - Solventum Corp (0001964738) (Issuer)

      5/2/25 4:38:20 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Cox Carrie Smith

      4 - Solventum Corp (0001964738) (Issuer)

      5/2/25 4:34:40 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Devore Susan D.

      4 - Solventum Corp (0001964738) (Issuer)

      5/2/25 4:31:57 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Solventum Reports First Quarter 2025 Financial Results

      Reported sales increased 2.6%; organic sales increased 4.3%Increases full year organic sales growth outlook by 50 bps to +1.5% to +2.5%ST. PAUL, Minn., May 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales increased 2.6% to $2.1 billion; up 4.3% on an organic basisGAAP diluted earnings per share of $0.78; adjusted diluted earnings per share of $1.34Operating cash flow of $29 million; free cash flow of $(80) million"Our first quarter fiscal year 2025 results reflect soli

      5/8/25 4:05:00 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum to Participate in the 2025 BofA Securities Health Care Conference

      ST. PAUL, Minn., May 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today its executives will participate in a fireside chat at the 2025 BofA Securities Health Care Conference on Tuesday, May 13, 2025, beginning at approximately 2:20 p.m. PST in Las Vegas, NV. A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com. About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest chal

      5/8/25 4:05:00 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum to Report First Quarter Fiscal 2025 Earnings on May 8, 2025

      ST. PAUL, Minn., April 17, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its first quarter fiscal 2025 financial results on Thursday, May 8, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, May 8, 2025 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 International dial-in: +1 (646

      4/17/25 4:05:00 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Solventum Corporation

      SC 13G/A - Solventum Corp (0001964738) (Subject)

      11/12/24 5:47:11 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Solventum Corporation

      SC 13G/A - Solventum Corp (0001964738) (Subject)

      11/4/24 1:47:43 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    Financials

    Live finance-specific insights

    See more
    • Solventum Reports First Quarter 2025 Financial Results

      Reported sales increased 2.6%; organic sales increased 4.3%Increases full year organic sales growth outlook by 50 bps to +1.5% to +2.5%ST. PAUL, Minn., May 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales increased 2.6% to $2.1 billion; up 4.3% on an organic basisGAAP diluted earnings per share of $0.78; adjusted diluted earnings per share of $1.34Operating cash flow of $29 million; free cash flow of $(80) million"Our first quarter fiscal year 2025 results reflect soli

      5/8/25 4:05:00 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum to Report First Quarter Fiscal 2025 Earnings on May 8, 2025

      ST. PAUL, Minn., April 17, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its first quarter fiscal 2025 financial results on Thursday, May 8, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, May 8, 2025 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 International dial-in: +1 (646

      4/17/25 4:05:00 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum Reports Fourth Quarter 2024 Financial Results and Introduces 2025 Full-Year Guidance

      Reported sales increased 1.9% to $2.074 billion; organic sales increased 2.3%GAAP diluted Earnings Per Share (EPS) of $0.17; adjusted EPS1 of $1.41Generated $219 million in cash from operations; free cash flow of $92 millionIntroduces full-year 2025 organic sales growth, adjusted EPS and free cash flow guidanceST. PAUL, Minn., Feb. 27, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the fourth quarter ended December 31, 2024. "Solventum executed another quarter of solid performance, enabling us to deliver full year 2024 at the high end of our ex

      2/27/25 4:05:00 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    SEC Filings

    See more
    • SEC Form 10-Q filed by Solventum Corporation

      10-Q - Solventum Corp (0001964738) (Filer)

      5/9/25 12:24:15 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Solventum Corp (0001964738) (Filer)

      5/8/25 4:13:51 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Solventum Corp (0001964738) (Filer)

      5/2/25 4:12:15 PM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Solventum Corporation with a new price target

      Mizuho initiated coverage of Solventum Corporation with a rating of Neutral and set a new price target of $70.00

      12/4/24 7:49:27 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Stifel initiated coverage on Solventum Corporation with a new price target

      Stifel initiated coverage of Solventum Corporation with a rating of Buy and set a new price target of $82.00

      10/8/24 7:35:48 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Piper Sandler initiated coverage on Solventum Corporation with a new price target

      Piper Sandler initiated coverage of Solventum Corporation with a rating of Neutral and set a new price target of $71.00

      10/7/24 8:25:35 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care

    $SOLV
    Leadership Updates

    Live Leadership Updates

    See more
    • Ampersand Biomedicines Appoints Elizabeth Mily to Board of Directors

      BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics. "We are thrilled to welcome Elizabeth to Ampersand's Board as we leverage our AND Platform to

      2/11/25 8:00:00 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing

      Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker BOSTON, Jan. 8, 2025 /PRNewswire/ -- The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Eliza

      1/8/25 6:30:00 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care
    • Solventum Names Surgeon and Diagnostics Pioneer Dr. Ryan Egeland as Chief Medical Officer

      ST. PAUL, Minn., Oct. 10, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that Dr. Ryan Egeland, MD, has been named chief medical officer. Dr. Egeland is responsible for leading Solventum's Global Medical and Clinical Affairs team, amplifying the voice of clinicians and patients. In this role, he will focus on fostering industry collaboration and identifying innovation and market expansion opportunities at the intersection of scientific rigor, clinical need, and commercial practicality. Dr. Egeland will report to Chris Barry, executive vice president and group presi

      10/10/24 9:00:00 AM ET
      $SOLV
      Medical/Dental Instruments
      Health Care